(Q40098317)

English

Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy

scientific article published on July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

author name string

Akihiro Tomita

1

1 reference

Europe PubMed Central

17 September 2017

Junji Hiraga

2

1 reference

Europe PubMed Central

17 September 2017

Hitoshi Kiyoi

3

1 reference

Europe PubMed Central

17 September 2017

Manabu Ninomiya

4

1 reference

Europe PubMed Central

17 September 2017

Takumi Sugimoto

5

1 reference

Europe PubMed Central

17 September 2017

Masafumi Ito

6

1 reference

Europe PubMed Central

17 September 2017

Tomohiro Kinoshita

7

1 reference

Europe PubMed Central

17 September 2017

Tomoki Naoe

8

1 reference

Europe PubMed Central

17 September 2017

publication date

1 July 2007

1 reference

Europe PubMed Central

17 September 2017

International Journal of Hematology

1 reference

Europe PubMed Central

17 September 2017

86

1 reference

Europe PubMed Central

17 September 2017

1

1 reference

Europe PubMed Central

17 September 2017

49-57

1 reference

Europe PubMed Central

17 September 2017

https://scigraph.springernature.com/pub.10.1532/ijh97.07028

0 references

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disappearance of minimal residual lymphoblastic leukemia cells 6 months after allogeneic bone marrow transplantation without GVHD

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of chromatin disruption and histone acetylation in thyroid hormone receptor action: implications in the regulation of HIV-1 LTR.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recruitment of N-CoR/SMRT-TBLR1 corepressor complex by unliganded thyroid hormone receptor for gene repression during frog development

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparing antibody and small-molecule therapies for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epitope recognized by rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoglobulin variable region structure and B-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epigenetics in human disease and prospects for epigenetic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure of the human immunoglobulin μ locus: Characterization of embryonic and rearranged J and D genes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody therapy for B-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/17675267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1532/IJH97.07028

1 reference

Europe PubMed Central

17 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40098317&oldid=2133499622"